Decompressive Craniectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Decompressive craniectomy (DC) is a life-saving emergency neurosurgical procedure in which a large section of the skull (typically 12-15 cm in diameter) is removed to allow the swelling brain to expand outward through the cranial defect, thereby preventing catastrophic rise in intracranial pressure (ICP) and the resulting brainstem herniation that would otherwise cause irreversible brain injury and death. The skull is a rigid bony box — unlike most body compartments, it has no capacity to expand. When the brain swells due to injury, infarction, haemorrhage, or infection, ICP rises exponentially. Once ICP exceeds cerebral perfusion pressure, cerebral blood flow ceases, and without surgical decompression, irreversible ischaemic injury and death follow.

Decompressive craniectomy is performed as either a primary procedure (when the neurosurgeon anticipates or observes severe brain swelling at the time of initial surgery, for example during evacuation of a haematoma) or as a secondary procedure in the ICU (performed when ICP monitoring shows sustained ICP elevation >20-25 mmHg refractory to all maximal medical management — osmotherapy, barbiturate coma, controlled hyperventilation, hypothermia). The standard unilateral decompressive hemicraniectomy for hemispheric injuries removes the frontotemporoparietal skull, decompressing the entire hemisphere. Bilateral decompressive craniectomy is performed for conditions causing global cerebral swelling.

Following DC, the brain herniates outward through the cranial defect (transcranial herniation), the swollen hemisphere is decompressed, ICP typically falls dramatically, and cerebral perfusion is restored. The removed bone flap is either stored in a freezer at the hospital or implanted subcutaneously in the patient's abdominal wall. Cranioplasty — replacement of the skull with the original bone flap or a custom titanium or PEEK implant — is performed as a planned separate procedure 6 weeks to 6 months later once the acute crisis has resolved and the patient has recovered sufficient physiological stability.

The three most common indications for decompressive craniectomy are: (1) Malignant middle cerebral artery (MCA) infarction — massive ischaemic stroke affecting the entire MCA territory causing fatal brain swelling in approximately 10-15% of large vessel MCA strokes (the DESTINY, HAMLET, and DECIMAL trials established DC as life-saving in this context); (2) Severe traumatic brain injury (TBI) — the most common indication globally, where diffuse cerebral oedema or large contusions cause refractory ICP elevation not controllable with medical measures; and (3) Spontaneous intracerebral haemorrhage — particularly large supratentorial haematomas with significant midline shift and clinical deterioration.

Additional indications include fulminant hepatic encephalopathy causing acute intracranial hypertension, cerebral venous sinus thrombosis with malignant infarction, post-cardiac arrest brain oedema in selected cases, severe tuberculous or bacterial meningitis with refractory ICP, and Reye syndrome in paediatric patients. Paediatric DC is also performed for traumatic brain injury and refractory status epilepticus-related cerebral oedema.

Patient selection for decompressive craniectomy is one of the most ethically complex decisions in neurosurgery, as the procedure reduces mortality but may leave surviving patients with severe neurological disability. The DESTINY II trial (DC for malignant MCA infarction in patients >60 years) showed a reduction in 6-month mortality from 70% to 33%, but with 68% of survivors having severe disability — raising profound questions about quality of life versus survival. For younger patients with malignant MCA infarction (DESTINY, HAMLET, DECIMAL trials, age 18-60), DC halved 1-year mortality (from ~80% to ~20%) with the majority of survivors achieving modified Rankin Scale score ≤3 (functional independence) at long-term follow-up.

Contraindications include bilateral fixed dilated pupils indicating brainstem herniation with no residual cerebral perfusion (futile surgery), severe pre-existing disability precluding meaningful recovery, documented advance directive refusing major surgical intervention, age over 80 (where evidence for benefit is very limited), and significant comorbidities making survival from the underlying condition or the surgical procedure itself unlikely. The decision must involve the multidisciplinary team (neurosurgeon, intensivist, neurologist) and family/surrogate decision-makers, with explicit discussion of likely outcomes and quality of life expectations.

Unilateral decompressive hemicraniectomy (the standard procedure for hemispheric lesions) removes a large temporoparietal or frontoparietal bone flap (12-15 cm diameter), opens the dura mater widely, and may include partial temporal lobe resection (temporal lobectomy) in the setting of uncal herniation to provide additional decompressive space. Bifrontal craniectomy is performed for anterior fossa and bilateral frontal swelling (common in severe TBI, anterior communicating artery aneurysm rupture). Posterior fossa decompressive craniectomy is performed for cerebellar haemorrhage or infarction causing brainstem compression and hydrocephalus.

Maximal medical ICP management — which always precedes or accompanies consideration of DC — includes: head-of-bed elevation 30 degrees, osmotherapy (mannitol or hypertonic saline boluses), controlled moderate hyperventilation (to PaCO2 30-35 mmHg), hypothermia (33-36°C), barbiturate coma, and CSF drainage via external ventricular drain (EVD). When these measures fail to control ICP below 20-25 mmHg, DC is considered. ICP monitoring via intraparenchymal probe or EVD is the standard of care in most intensive care units managing severe TBI, providing real-time ICP data to guide both medical and surgical treatment decisions. The decision between primary craniectomy (removing bone at initial surgery) and secondary craniectomy (when craniotomy fails to achieve adequate decompression) is guided by ICP monitoring trajectories, clinical response to tiered medical management, and neuroimaging findings, with established thresholds and timing criteria defined in international neurocritical care guidelines.

Decompressive craniectomy reduces intracranial pressure immediately and dramatically — ICP typically falls by 50-80% within hours of the procedure. The landmark DESTINY, HAMLET, and DECIMAL randomised controlled trials conclusively demonstrated that DC for malignant MCA infarction in patients aged 18-60 reduces 12-month mortality from approximately 75-80% in the medically treated group to approximately 20-25% in the surgical group, and significantly increases the proportion of patients achieving functional independence (mRS ≤3). RESCUEicp trial data for severe TBI showed DC reduced 12-month mortality from 48% to 26% versus continued medical management in refractory intracranial hypertension.

Functional outcomes for survivors are variable but substantially better than the natural history of untreated malignant swelling. Long-term follow-up studies from DESTINY and HAMLET show that the majority of young patients (under 50) surviving malignant MCA infarction following DC achieve independent functional status, with continued neurological recovery extending beyond 1-2 years post-stroke. Quality of life assessments in DC survivors show that many patients report acceptable or good quality of life when assessed at long-term follow-up — importantly, patients' own ratings of quality of life tend to be more positive than proxy assessments by clinicians or family members.

Decompressive craniectomy carries inherent neurosurgical risks amplified by the critical condition of patients undergoing the procedure. Intraoperative risks include life-threatening haemorrhage from bridging veins, venous sinus injury, or underlying brain injury; anaesthetic risks in critically ill patients; and acute deterioration from brain herniation through the cranial defect during positioning. Post-operative complications include delayed haematoma formation, hydrocephalus (requiring ventriculoperitoneal shunt), cerebral contusion or haemorrhagic transformation at the decompressed margin, and syndrome of the trephined (delayed neurological deterioration after craniectomy before cranioplasty, due to atmospheric pressure and CSF dynamics changes).

Infection — including wound infection, osteomyelitis of the stored bone flap, meningitis, and intracranial abscess — occurs in approximately 3-8% of cases and may preclude use of the autologous bone flap at cranioplasty. The craniectomy site requires a protective helmet whenever the patient is out of bed to prevent direct brain injury from impact. Paradoxical cerebral herniation (downward herniation through the defect due to CSF loss or hydrocephalus) can cause acute neurological deterioration and death. Seizures are common following TBI and stroke and require prophylactic or therapeutic antiepileptic drug management.

After decompressive craniectomy, patients are managed in the neurological ICU with continuous ICP monitoring, mechanical ventilation, sedation management, and multimodal physiological monitoring. The ICU phase typically lasts 2-6 weeks depending on the underlying condition and rate of recovery. Weaning from ventilation, assessment of consciousness level (GCS monitoring, assessment for disorders of consciousness — vegetative state, minimally conscious state), and early rehabilitation commence as the acute crisis resolves.

Cranioplasty (skull reconstruction) is planned 6 weeks to 6 months after decompressive craniectomy, optimally timed when the patient is medically stable, neurological recovery has plateaued, the scalp wound is fully healed, and the risk of infection is minimised. If the autologous bone flap is intact (stored frozen or in the abdomen), it is reimplanted; otherwise a custom titanium or PEEK implant is fabricated using CT-based 3D modelling. Long-term neurological rehabilitation — including physiotherapy, occupational therapy, speech and language therapy, neuropsychological rehabilitation, and vocational rehabilitation — continues for months to years, with neurological recovery extending substantially beyond the initial recovery period in many patients.

Decompressive craniectomy is a critical care emergency procedure; costs are covered by national health systems and emergency medical insurance in most countries. In the USA, total hospitalisation costs including neurosurgery, ICU care, and rehabilitation following malignant stroke or severe TBI managed with DC can exceed USD 200,000-500,000. NHS in the UK provides DC and all associated critical care free of charge.

For international patients, neurosurgical emergency management is available at tertiary hospitals in India, Thailand, Singapore, and the UAE with internationally trained neurosurgeons and Level 1 trauma infrastructure. JCI-accredited hospitals in these countries provide DC and neurocritical care at 50-70% of USA private rates — relevant primarily for planned complex cases and for medical tourists who experience neurosurgical emergencies while abroad. AIIMS, NIMHANS, Apollo, and Fortis hospitals in India have internationally recognised neurosurgery departments with substantial DC experience.

All available maximal medical ICP management strategies are applied before considering DC: osmotherapy (mannitol, hypertonic saline), controlled hyperventilation, head positioning, sedation and analgesia, hypothermia, and barbiturate coma for refractory ICP. These measures are continued alongside DC in the post-operative period. For malignant MCA infarction in patients above 80 or with very severe deficits, palliative care (withdrawal of life-sustaining treatment) is a legitimate alternative to DC, particularly when the patient's pre-morbid quality of life, previously expressed wishes, and likely post-DC disability are considered.

For cerebellar haematoma causing brainstem compression, surgical haematoma evacuation without DC (suboccipital craniectomy with clot removal) may be appropriate. Endovascular treatment of large vessel occlusion strokes (mechanical thrombectomy within 6-24 hours of onset) is the most effective intervention for MCA stroke — restoring perfusion before malignant swelling develops — and may reduce or eliminate the need for DC when performed successfully in the early time window.